glp-1/gip dual agonist Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Dual and Triple Gut Peptide

Of these two drugs, only orlistat was approved for long term use

Metabolic indicators that may be associated with reduced GLP-1 activity include: Persistent elevated blood glucose levels , particularly postprandial (after-meal) hyperglycaemia Difficulty achieving or maintaining a healthy weight despite dietary efforts Increased appetite and reduced satiety after meals, leading to frequent snacking Diagnosis of type 2 diabetes or non-diabetic hyperglycaemia (NDH, sometimes called prediabetes), conditions where GLP-1 response is often blunted Features of metabolic syndrome , including central obesity, hypertension, and dyslipidaemia Individuals may also notice practical symptoms such as feeling hungry shortly after eating substantial meals, experiencing energy crashes following carbohydrate-rich foods, or finding portion control particularly challenging

The MotherToBaby position MotherToBaby, a service of the Organization of Teratology Information Specialists, notes that while studies are limited, the available data on injectable semaglutide and tirzepatide suggest low risk during breastfeeding

CAROLYN BRAMANTE: Yeah, so exactly, that's one of the concerns, especially in older adults, is that weight loss usually goes with losing muscle and fat-- fat tissue

It's also worth thinking about the placebo effect

Acknowledgments I thank Lily Lu, MD, PhD for her critical comments and David Liu and Erika Liu for their assistance with editing